Vista Pharmaceuticals' Board has approved the allotment of 1.02 Cr fully convertible warrants to non-promoters on a preferential basis.

Each warrant is priced at ₹12, making the total consideration ₹12.30 Cr.

The company has already received ₹3.07 Cr, representing 25% of the issue price.

This allotment is a portion of a larger approved issuance, with the remaining warrants not yet allotted due to a technical issue preventing the receipt of their initial 25% payment.

This move will bring in new capital, strengthening the company's financial position.